Tyler J. Wilhite, MD, discussed coordinating with rheumatology, orthopedic surgery, and primary care when treating patients with osteoarthritis with low-dose radiation therapy.

The FDA set a June 15, 2027, target action date for sacituzumab tirumotecan in endometrial cancer previously treated with ...

In a retrospective study, high AI-derived whole-body tumor volume on PSMA PET-CT was associated with a 3.20-fold higher risk of death in prostate cancer.

Tyler J. Wilhite, MD, discussed scaling low-dose radiation therapy for osteoarthritis from 1 patient to nearly 20 centers and the referral work behind it.

Findings may provide reassurance to patients with early-stage disease that surgery may help improve survival rates.

Grade 3/4 neurotoxicity in patients prompted a partial clinical hold on the PALISADES-1 and PALISADES-2 trials of KITE-753 in large B-cell lymphoma. The PALISADES-1 (NCT04989803) and PALISADES-2 ...

Hope S. Rugo, MD, discussed KEYNOTE-B49 data showing pembrolizumab plus chemotherapy improved PFS in PD-L1-positive HR+/HER2- ...

Sunnie Kim, MD, discusses postoperative management for patients without a pathologic response after neoadjuvant durvalumab ...

Dirk Schadendorf, MD, discussed final STARBOARD data with encorafenib, binimetinib, and pembrolizumab and its role in BRAF V600–mutant melanoma care.

Zev A. Wainberg, MD, MSc, discussed why neither the first-line regimen nor the second-line chemotherapy comparator altered ...

Rutika Mehta, MD, MPH, shares her framework for growth factor support, global dose reductions, and dropping agents during FLOT therapy. In an interview with CancerNetwork®, Rutika Mehta, MD, MPH, ...

Rocbrutinib plus R-CHOP yielded a 100% ORR and an 86.7% CR rate in 15 patients with untreated non-GCB DLBCL, warranting randomized evaluation.